[The study of cucurbitacin BE polylactic acid nanoparticles delivering cucurbitacin BE to metastasized cervical lymph nodes in mice with oral cancer].
OBJECTIVE
The aim of this study was to investigate the delivery of Cucurbitacin BE to cervical lymph nodes by peri-cancer submucosal injection of the average diameter 85 nm Cucurbitacin BE polylactic acid nanoparticles (CuBE-PLA-NP).


METHODS
Cervical lymph node metastasis model of mice oral cancer was established and CuBE-PLA-NP and CuBE were injected in peri-cancer submucosal of the mice respectively, the concentration in blood, heart, liver, spleen, lung, kidney and cervical lymph node were measured by high performance liquid chromatography at fifteen time points, Targeted cervical lymph nodes were evaluated by targeting index, selectivity index, targeting efficiency, relative targeting efficiency and ratio of maximum concentration.


RESULTS
(1) The CuBE concentration in the cervical lymph nodes after CuBE-PLA-NP injection was far higher than that after CuBE injection at every time point, the CuBE duration in the cervical lymph nodes in CuBE-PLA-NP group was far longer than that in CuBE group; (2) The five targeted values of the cervical lymph nodes in CuBE-PLA-NP group was far higher than that in CuBE group; (3) The CuBE concentration in blood, heart, liver, spleen, lung and kidney in CuBE-PLA-NP group was far lower than that in CuBE group.


CONCLUSIONS
The CuBE-PLA-NP can specifically deliver CuBE to the cervical lymph nodes by peri-cancer submucosal injection, increase CuBE concentration and duration in metastasized cervical lymph nodes, and decrease drug concentration of other organs.
Yang
Kai
K
Department of Oral and Maxillofacial Surgery, First Affiliated Hospital, Chongqing University of Medical Sciences, Chongqing 400016, China.
Wen
Yuming
Y
Wang
Changmei
C
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000601:surgery; D054728:Cucurbitacins; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005260:Female; D019344:Lactic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics; D008198:Lymph Nodes / Q000378:metabolism / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D051379:Mice; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000601:surgery; D036103:Nanotechnology; D009333:Neck; D010316:Particle Size; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage / Q000493:pharmacokinetics; D014315:Triterpenes / Q000008:administration & dosage* / Q000493:pharmacokinetics*
D000972:Antineoplastic Agents, Phytogenic; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D011091:Polyesters; D011108:Polymers; D014315:Triterpenes; D019344:Lactic Acid; C033616:poly(lactide); D054728:Cucurbitacins